The standard regimen of the BNT162b2 mRNA vaccine for SARS-CoV-2 includes two doses administered three weeks apart. However, some public health authorities spaced these doses, raising questions about efficacy. We analyzed longitudinal humoral responses against the D614G strain and variants of concern for SARS-CoV-2 in a cohort of SARS-CoV-2-naive and previously infected individuals who received the BNT162b2 mRNA vaccine with sixteen weeks between doses. While administering a second dose to previously infected individuals did not significantly improve humoral responses, these responses significantly increased in naive individuals after a 16-week spaced second dose, achieving similar levels as in previously infected individuals. Comparing these responses to those elicited in individuals receiving a short (4-week) dose interval showed that a 16-week interval induced more robust responses among naive vaccinees. These findings suggest that a longer interval between vaccine doses does not compromise efficacy and may allow greater flexibility in vaccine administration.

Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses / A. Tauzin, S.Y. Gong, G. Beaudoin-Bussières, D. Vézina, R. Gasser, L. Nault, L. Marchitto, M. Benlarbi, D. Chatterjee, M. Nayrac, A. Laumaea, J. Prévost, M. Boutin, G. Sannier, A. Nicolas, C. Bourassa, G. Gendron-Lepage, H. Medjahed, G. Goyette, Y. Bo, J. Perreault, L. Gokool, C. Morrisseau, P. Arlotto, R. Bazin, M. Dubé, G. De Serres, N. Brousseau, J. Richard, R. Rovito, M. Côté, C. Tremblay, G.C. Marchetti, R. Duerr, V. Martel-Laferrière, D.E. Kaufmann, A. Finzi. - In: CELL HOST & MICROBE. - ISSN 1931-3128. - 30:1(2022 Jan 12), pp. 97-109. [10.1016/j.chom.2021.12.004]

Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses

R. Rovito;G.C. Marchetti;
2022

Abstract

The standard regimen of the BNT162b2 mRNA vaccine for SARS-CoV-2 includes two doses administered three weeks apart. However, some public health authorities spaced these doses, raising questions about efficacy. We analyzed longitudinal humoral responses against the D614G strain and variants of concern for SARS-CoV-2 in a cohort of SARS-CoV-2-naive and previously infected individuals who received the BNT162b2 mRNA vaccine with sixteen weeks between doses. While administering a second dose to previously infected individuals did not significantly improve humoral responses, these responses significantly increased in naive individuals after a 16-week spaced second dose, achieving similar levels as in previously infected individuals. Comparing these responses to those elicited in individuals receiving a short (4-week) dose interval showed that a 16-week interval induced more robust responses among naive vaccinees. These findings suggest that a longer interval between vaccine doses does not compromise efficacy and may allow greater flexibility in vaccine administration.
ADCC; COVID-19; Coronavirus; SARS-CoV-2; Spike glycoproteins; delayed mRNA vaccine regimen; humoral responses; neutralization; variants of concern; variants of interest
Settore MED/17 - Malattie Infettive
12-gen-2022
Article (author)
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S1931312821005692-main.pdf

accesso riservato

Descrizione: Article
Tipologia: Publisher's version/PDF
Dimensione 2.3 MB
Formato Adobe PDF
2.3 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/1029428
Citazioni
  • ???jsp.display-item.citation.pmc??? 56
  • Scopus 54
  • ???jsp.display-item.citation.isi??? 50
social impact